Ignite Creation Date:
2024-05-05 @ 5:10 PM
Last Modification Date:
2024-10-26 @ 9:29 AM
Study NCT ID:
NCT00404924
Status:
COMPLETED
Last Update Posted:
2016-09-30
First Post:
2006-11-28
Brief Title:
ZD6474 ZACTIMA Phase III Study in EGFR Failures
Sponsor:
Genzyme a Sanofi Company
Organization:
Sanofi
Study Overview
Official Title:
A Phase III Study to Assess the Efficacy of ZD6474 ZACTIMA Plus Best Supportive Care Versus Best Supportive Care in Patients With Locally Advanced or Metastatic Stage IIIB-IV Non-Small Cell Lung Cancer After Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor EGFR TKI
Status:
COMPLETED
Status Verified Date:
2016-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is being carried out to assess if adding ZD6474 to best supportive care BSC is more effective than best supportive care alone for the treatment of patients with non-small cell lung cancer whose disease has recurred after previous chemotherapy and an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor EGFR TKI ZD6474 is a new anti-cancer drug in development that works in a different way to standard chemotherapy drugs It targets the growth of new blood vessels to a tumour and thereby might slow the rate at which the tumour may grow Early studies indicate that ZD6474 has a positive effect on the time that a tumour may take to progress to a further stage Approximately 930 patients will take part in this study It will be conducted in hospitals and clinics in North and South America Europe and Asia
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| EUDRACT Number 2006-002384-12 | None | None | None |